Asparaginase erwinia chrysanthemi is under clinical development by Porton Biopharma and currently in Phase III for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase III drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Asparaginase erwinia chrysanthemi’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Asparaginase erwinia chrysanthemi overview
Asparaginase Erwinia Chrysanthemi (Erwinase, Erwinaze) is an enzyme isolated from the bacterium Erwinia chrysanthemi (E. carotovora). It is formulated as lyophilized powder for solution for intramuscular, intravenous route of administration. It is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.
Erwinase (Asparaginase Erwinia chrysanthemi) is under development for the treatment of acute lymphoblastic leukemia (ALL), and It was also under development for lymphoblastic lymphoma and pain.
Porton Biopharma overview
Porton Biopharma discovers, develops, manufactures and sells biopharmaceutical products. It is a manufacturer of anthrax vaccine. Porton Biopharma is headquartered in Salisbury, Wiltshire, the UK.
For a complete picture of Asparaginase erwinia chrysanthemi’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
